TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Joseph, J V ^a   Conroy, S ^a   Tomar, T ^a   Eggens Meijer, E ^a   Bhat, K ^b   Copray, S ^a   Walenkamp, A M E ^a   Boddeke, E ^a   Balasubramanyian, V ^a   Wagemakers, M ^a   Den Dunnen, W F A ^a   Kruyt, F A E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; SMAD2 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; HOMEODOMAIN PROTEIN; SMAD2 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; ZEB1 PROTEIN, HUMAN;

ANIMAL MODEL; ARTICLE; CELL INVASION; CELL MIGRATION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; CYTOKINE RELEASE; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR CLASSIFICATION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CELL MOTION; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SCID MOUSE;

MUS;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GLIOBLASTOMA; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84919949972     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.395     Document Type: Article

References (39)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-996.
3. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21:2683-2710.
4. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 2013; 10:14-26.
5. Cancer Genome Atlas Research Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-1068.
6. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22: 425-437.
7. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
8. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17: 98-110.
9. Huse JT, Phillips HS, Brennan CW. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011; 59: 1190-1199.
10. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol 2010; 12: 49-57.
11. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005; 11: 3326-3334.
12. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-522.
13. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010; 463: 318-325.
14. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25: 2594-2609.
15. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F et al. Mesenchymal differentiation mediated by NF-?B promotes radiation resistance in glioblastoma. Cancer Cell 2013; 24: 331-346.
16. Rich JN. The role of transforming growth factor-beta in primary brain tumors. Front Biosci 2003; 8: e245-e260.
17. Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001; 52:401-410.
18. Joseph JV, Balasubramaniyan V, Walenkamp A, Kruyt FA. TGF-ß as a therapeutic target in high grade gliomas - promises and challenges. Biochem Pharmacol 2013; 85:478-485.
19. Zhang M, Kleber S, Rfhrich M, Timke C, Han N, Tuettenberg J et al. Blockade of TGF-ß signaling by the TGFßR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011; 71:7155-7167.
20. Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-ß. Cancer Res 2012; 72:4119-4129.
21. Akhurst RJ, Hata A. Targeting the TGFß signalling pathway in disease. Nat Rev Drug Discov 2012; 11: 790-811.
22. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A. Targeted therapy for high-grade glioma with the TGF-ß2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011; 13: 132-142.
23. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodósn L, Folch G, Carmona MA. TGF-ß receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010; 18: 655-668.
24. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-715.
25. Hance MW, Dole K, Gopal U, Bohonowych JE, Jezierska-Drutel A, Neumann CA et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem 2012; 287: 37732-37744.
26. Xiao D, He J. Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2010; 2:154-159.
27. Pakala SB, Singh K, Reddy SD, Ohshiro K, Li DQ, Mishra L et al. TGF-ß1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene 2011; 30:2230-2241.
28. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172.
29. Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to mesenchymal transition by transforming growth factor-beta. Cancer Sci 2005; 96: 791-800.
30. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009; 90: 222-231.
31. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW et al. p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-323.
32. Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. ß-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)- activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA 2011; 108:19204-19209.
33. Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009; 15: 315-327.
34. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013; 110: 4009-4014.
35. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119: 1420-1428.
36. Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, Sarkisian MR et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 2013; 5: 1196-1212.
37. Drabsch Y, He S, Zhang L, Snaar-Jagalska BE, Ten Dijke P. Transforming growth factor beta signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast Cancer Res 2013; 15: R106.
38. Massagué J, Like B. Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J Biol Chem 1985; 260: 2636-2645.
39. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61-74.